Taylor Morrison Home
TMHC
Meritage Homes
MTH
D.R. Horton
DHI
Lennar Corp
LEN
Toll Brothers
TOL
US Stock MarketDetailed Quotes
SWTX SpringWorks Therapeutics
- 54.030
- -2.530-4.47%
Close Feb 25 16:00 ET
4.05BMarket Cap-15.53P/E (TTM)
56.140High53.310Low3.38MVolume55.950Open56.560Pre Close183.25MTurnover4.59%Turnover RatioLossP/E (Static)74.94MShares62.00052wk High8.42P/B3.98BFloat Cap28.21052wk Low--Dividend TTM73.69MShs Float96.480Historical High--Div YieldTTM5.00%Amplitude13.600Historical Low54.194Avg Price1Lot Size
Trending Stocks
Fed Rate Cut Beneficiaries Fed Rate Cut Beneficiaries
Stocks that are expected to benefit from a Federal Reserve rate cut. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in Fed Rate Cut Beneficiaries, ranked from highest to lowest based on real-time market data. Stocks that are expected to benefit from a Federal Reserve rate cut. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in Fed Rate Cut Beneficiaries, ranked from highest to lowest based on real-time market data.
SpringWorks Therapeutics Stock Forum
Can SpringWorks' Dual Drug Strategy Transform Its Financial Future? Q4 Results Reveal Key Insights
Historic FDA Approval: Groundbreaking NF1-PN Treatment Shows Remarkable 52% Response in Children
Breakthrough FDA Approval: New Drug Shows Remarkable 52% Response Rate in Children with Rare Tumor Disease
FDA: Approved Mirdametinib, for Adult & Pediatric Patients 2 Years of Age & Older With Nf1 Who Have Symptomatic Pn Not Amenable to Complete Resection
-Billionaire investor Stanley Druckenmiller told Bloomberg on Wednesday that selling all his Nvidia stock this year was a “big mistake.”
-Nvidia was Druckenmiller's top holding a year ago, but he sold it after the stock tripled in 2023.
-The shares are up another 174% this year, and Druckenmiller has missed much of the continuing rally.
Stanley Druckenmiller is an American billionair...
$Iovance Biotherapeutics (IOVA.US)$ Phase 2
$Supernus Pharmaceuticals (SUPN.US)$ Phase 2a
$BRANDES INTERNATIONAL ETF (BINV.US)$ Phase 2a
$MorphoSys (MOR.US)$ Phase 2
$Nuvation Bio (NUVB.US)$ Phase 2
$ALX Oncology (ALXO.US)$ Phase 2
$BioXcel Therapeutics (BTAI.US)$ Phase 2
$Purple Biotech (PPBT.US)$ Phase 2
$Arcus Biosciences (RCUS.US)$ Phase 2
$Medicenna Therapeutics (MDNAF.US)$ Phase 2b
$Affimed NV (AFMD.US)$ Phase 2
$Barinthus Biotherapeutics (BRNS.US)$ Phase 2b...
» Holdings in Top 20: 58.46%
» Qtr over Qtr Change**: 28.47%
Top Holdings:
$Cerevel Therapeutics Holdings (CERE.US)$
$Amicus Therapeutics (FOLD.US)$
$Iovance Biotherapeutics (IOVA.US)$
$Arcellx (ACLX.US)$
$Nuvalent (NUVL.US)$
$Apogee Therapeutics (APGE.US)$
$Inhibrx (INBX.US)$
$Fusion Pharmaceuticals (FUSN.US)$
$Rhythm Pharmaceuticals (RYTM.US)$
$Vaxcyte (PCVX.US)$
$Soleno Therapeutics (SLNO.US)$
$Medtronic (MDT.US)$
$Madrigal Pharmaceuticals (MDGL.US)$
...
⇨ held by 5 biopharma-focused hedge funds! 🔥
$Arcellx (ACLX.US)$ : Anito-cel (Ph 2)
$Adaptimmune Therapeutics (ADAP.US)$ : Afami-cel (PDUFA) ⏳
$Bicycle Therapeutics (BCYC.US)$ : BT8009 (Ph 1/2)
$Centessa Pharmaceuticals (CNTA.US)$ : LB101 (Ph 1/2)
$Day One Biopharmaceuticals (DAWN.US)$ : Tovorafenib (PDUFA) (check comments for details)
$Fate Therapeutics (FATE.US)$ : FT576 (Ph 1)
$Fusion Pharmaceuticals (FUSN.US)$ : FPI-2265 (Ph 2)
$GRCL: ...
No comment yet